Obsessive-Compulsive Disorder
Conditions
Keywords
Adolescence, Adult, Antipsychotic Agents, Dopamine Antagonists, Female, Fluvoxamine, Haloperidol, Human, Male, Middle Age, Obsessive-Compulsive Disorder, Placebos, Serotonin Uptake Inhibitors, Tourette Syndrome, Tryptophan, Drug Combinations, Antipsychotic Agents -- *therapeutic use, Fluvoxamine -- *therapeutic use, Haloperidol -- *therapeutic use, Obsessive-Compulsive Disorder -- *drug therapy, Obsessive-Compulsive Disorder -- physiopathology, Serotonin Uptake Inhibitors -- *therapeutic use
Brief summary
The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
Detailed description
To advance the neurobiology and treatment of obsessive-compulsive disorder (OCD) by focusing on Tourette's Syndrome (TS)-spectrum OCD as a possible homogeneous form of OCD, and investigating the relevance of intact 5-hydroxytryptamine (5-HT) function to the mechanism of anti-OC drug action. The validity of TS-spectrum OCD as a distinct subtype is assessed using a detailed clinical, family, drug treatment response profile in adult OCD patients. In Study I, patients are divided prospectively into 2 putative subtypes (TS-spectrum and non-TS-spectrum OCD) on the basis of clinical history and direct, structured interviews of family members (approximately 400 interviews). In Study II, patients enter an 8-week single-blind trial with the potent and selective 5-HT reuptake inhibitor fluoxetine (FX). Patients with an incomplete response to FX alone (approximately 64 patients) are randomized to a 4-week double-blind trial of FX in combination with the dopamine (DA) 2 antagonist olanzapine (OLA) or placebo (PLA).
Interventions
DRUGolanzapine + fluoxetine
DRUGplacebo + fluoxetine
Sponsors
National Institute of Mental Health (NIMH)
University of Florida
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
14 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
required that subjects, ages 14-70 years, have at least a 1-year duration of a current Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) principal diagnosis of OCD. Furthermore, the OCD had to be defined by a rating of moderate or greater on the global severity item of the Clinical Global Impressions (CGI) scale and have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of 19 or greater.
Exclusion criteria
included primary depression, schizophrenia, or other psychotic disorders; active bipolar disorder; abuse of alcohol or other significant substance within 6 months; increased risk of seizures or history of neurosurgery, encephalitis, or significant head trauma; or a significant medical condition, such as heart, liver, or renal disease. Subjects with an intelligence quotient of less than 80 as determined with the Kaufman Brief Intelligence Test (Kaufman and Kaufman 1990) were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 25% reduction in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score from baseline | Baseline, Week s 1, 2, 4, 6, 8, 10, 12, and 14 |
Countries
United States
Outcome results
None listed